Hannah M Linden
Affiliation: University of Washington
- Attitudes toward participation in breast cancer randomized clinical trials in the African American community: a focus group studyHannah M Linden
Department of Medicine, Seattle Cancer Care Alliance, University of Washington, Seattle, WA 98109, USA
Cancer Nurs 30:261-9. 2007..Lessons learned from this study support the selection of a culturally diverse research staff and can guide the development of research protocols, recruitment efforts, and clinical procedures that are culturally sensitive and relevant...
- Novel methods and tracers for breast cancer imagingHannah M Linden
Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
Semin Nucl Med 43:324-9. 2013....
- Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancerHannah M Linden
Department of Medicine, University of Washington, Seattle, Washington, USA
Clin Cancer Res 17:4799-805. 2011..To determine, by molecular imaging, how in vivo pharmacodynamics of estrogen-estrogen receptor (ER) binding differ between types of standard endocrine therapy...
- Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?Hannah M Linden
Division of Medical Oncology, School of Medicine, University of Washington Medical Center, Seattle, WA, USA
Clin Cancer Res 12:5608-10. 2006
- Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancerHannah M Linden
Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
J Clin Oncol 24:2793-9. 2006..We tested the ability of FES-PET imaging to predict response to salvage hormonal treatment in heavily pretreated metastatic breast cancer patients, predominantly treated with aromatase inhibitors...
- Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancerLisa K Dunnwald
Department of Bioengineering, Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
J Clin Oncol 26:4449-57. 2008..Serial positron emission tomography (PET) has been shown to predict pathologic response in this setting. We evaluated serial quantitative PET tumor blood flow (BF) and metabolism as in vivo measurements to predict patient outcome...
- PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptakeLisa K Dunnwald
Division of Nuclear Medicine and Medical Oncology, University of Washington, Seattle, Washington 98109, USA
Clin Cancer Res 17:2400-9. 2011..Serial dynamic [(18)F]-FDG (fluorodeoxyglucose) PET scans were used to compare kinetic parameters with the standardized uptake value (SUV) as predictors of pathologic response, disease-free survival (DFS), and overall survival (OS)...
- Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)Jennifer M Specht
Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, G3 200, Seattle, WA 98109, USA
Breast Cancer Res Treat 105:87-94. 2007..Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment...
- Quantitative assessment of dynamic PET imaging data in cancer imagingMark Muzi
Department of Radiology, University of Washington, Seattle, WA 98195 6004, USA
Magn Reson Imaging 30:1203-15. 2012....
- Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designsBrenda F Kurland
aFred Hutchinson Cancer Research Center, Seattle, WA, USA
Clin Trials 10:886-95. 2013..However, it is often unknown how measurement error and bias in a multicenter trial will differ from that in single-institution studies...
- Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancerJennifer M Specht
Medical Oncology and Nuclear Medicine, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
Clin Cancer Res 16:2803-10. 2010..This analysis examines tumor metabolism and perfusion by tumor subtype...
- Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survivalLisa K Dunnwald
Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington 98195, USA
Cancer 103:680-8. 2005..The pathologic response of LABC to presurgical treatment regimens is a prognostic indicator of survival. The authors tested whether MIBI uptake posttherapy predicted survival...
- Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapyDavid A Mankoff
Division of Nuclear Medicine, University of Washington, Seattle, Washington 98195, USA
J Nucl Med 44:1806-14. 2003..To characterize in vivo tumor biology in patients with LABC, we performed serial measurements of blood flow and glucose metabolism in LABC patients over the course of neoadjuvant chemotherapy and compared measurements with response...
- 18F-FluoroestradiolLavanya Sundararajan
Department of Medicine, University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA
Semin Nucl Med 37:470-6. 2007..Preliminary data strongly point toward potential clinical utility for FES-PET, motivating further validation and future clinical trials with prospective endpoints tested under appropriate regulatory oversight...
- Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patientsBrenda F Kurland
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA
EJNMMI Res 2:34. 2012..Our study was designed to test for an early decline in FDG uptake in response to AI or T and to examine association with Ki-67 measures of early response...
- Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancerLanell M Peterson
Department of Radiology, University of Washington Medical Center, Seattle, WA 98195, USA
Nucl Med Biol 38:969-78. 2011..Assessment of factors that could affect the quantitative level of FES uptake is important as part of the validation of FES PET for evaluating regional ER expression in breast cancer...
- Effect of 18F-FDG uptake time on lesion detectability in PET imaging of early stage breast cancerKristen A Wangerin
Department of Bioengineering, University of Washington, Seattle, Washington
Tomography 1:53-60. 2015..These results imply that delayed PET imaging may reveal low-conspicuity lesions that would have otherwise gone undetected...
- A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)Lanell M Peterson
Radiology Nuclear Medicine, University of Washington Medical Center Seattle Cancer Care Alliance, Seattle, WA, USA
Mol Imaging Biol 16:431-40. 2014..16α-[(18)F]-fluoro-17β-estradiol positron emission tomography (FES-PET) quantifies estrogen receptor (ER) expression in tumors and may provide diagnostic benefit...
- Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is NewEunpi Cho
Department of Medicine, University of Washington, Seattle, WA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
Clin Breast Cancer 15:e277-85. 2015....
- Challenges in clinical studies with multiple imaging probesKenneth A Krohn
Radiology Department, Molecular Imaging Center, University of Washington, Seattle, WA 98195 6004, USA
Nucl Med Biol 34:879-85. 2007..The purpose of this article is to promote a critical discussion within the molecular imaging community because our future value to the overall biomedical community will be in supporting better treatment outcomes rather than in detection...
- Tumor receptor imagingDavid A Mankoff
Division of Nuclear Medicine, University of Washington, Seattle, Washington, USA
J Nucl Med 49:149S-63S. 2008....
- Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trialsRobert K Doot
Department of Radiology, University of Washington, Seattle, WA, USA Seattle Cancer Care Alliance, Seattle, WA, USA
Magn Reson Imaging 30:1291-300. 2012..These methods should be developed and implemented in multicenter clinical trials employing quantitative PET imaging of patients...
- Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)Hannah M Linden
Puget Sound Oncology Consortium, Southwest Oncology Group Statistical Center, Seattle, WA, USA
J Clin Oncol 25:656-61. 2007....
- Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?Nina Oestreicher
University of Washington, Seattle, Washington, USA
Genet Med 7:380-9. 2005..However, the outcomes associated with gene expression profiling are not clear, and guidelines for the appropriate use of genomic technologies have not been established...
- Evaluation of Cross-Calibrated 68Ge/68Ga Phantoms for Assessing PET/CT Measurement Bias in Oncology Imaging for Single- and Multicenter TrialsDarrin W Byrd
Department of Radiology, University of Washington, Seattle, Washington
Tomography 2:353-360. 2016..We conclude that these biases cannot be assumed constant over time. The kits provide a robust method to monitor PET scanner and dose calibrator biases, and resulting biases in standardized uptake values...
- Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatmentJoann G Elmore
Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98104 2499, USA
Med Care 43:141-8. 2005..Recent studies suggest differences in quality and timeliness of care received may be major contributing sources to the racial disparity in breast cancer detection and related outcomes...
- Myalgias and arthralgias associated with paclitaxelJulie A Garrison
Department of Pharmacy, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington, USA
Oncology (Williston Park) 17:271-7; discussion 281-2, 286-8. 2003....
- The use of stereotactic radiosurgery for brain metastases from breast cancer: who benefits most?Eunpi Cho
Department of Medicine, University of Washington, Seattle, WA, USA
Breast Cancer Res Treat 149:743-9. 2015..For patients with TNBC, prognosis is guarded following SRS, and there is an urgent need to develop more effective treatment strategies...
- An ounce of prevention or a pound of cure? Investing to improve breast cancer outcomes for African American womenHannah M Linden
J Clin Oncol 22:2517-8. 2004
- The cost of adjuvant chemotherapy in patients with early-stage breast carcinomaNina Oestreicher
Division of Research, Kaiser Permanente, Oakland, California 94612, USA
Cancer 104:2054-62. 2005..The objective of the current study was to evaluate the direct medical cost of adjuvant chemotherapy in women with early-stage breast carcinoma...
- Reducing disparities in breast cancer survival: a Columbia University and Avon Breast Cancer Research and Care Network SymposiumKaren Antman
Columbia University, New York City, NY, USA
Breast Cancer Res Treat 75:269-80. 2002..The Avon Foundation funded this symposium to bring together interested investigators to share programmatic experiences, data and innovative approaches to the problem...